Director/PDMR Shareholding

RNS Number : 2402D

AstraZeneca PLC

01 March 2022

 

1 March 2022 15:30 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that on 28 February 2022 awards of AstraZeneca American Depositary Shares (ADSs) vested to Dr Aradhana Sarin, Executive Director and Chief Financial Officer. Each ADS represents one half of an Ordinary Share of $0.25 in the Company.

In accordance with the Agreement and Plan of Merger, the awards were granted under the AstraZeneca Global Restricted Stock Plan at the time of closing of the acquisition of Alexion Pharmaceuticals, Inc. (Alexion) by the Company. The awards replaced in-flight Alexion awards originally granted to Dr Sarin between February 2018 and February 2021 under the Alexion 2017 Incentive Plan. The replacement awards vested on completion of their respective holding periods.

Following the withholding of shares to satisfy certain tax obligations arising on vesting, 67,677 ADSs vested.

For tax purposes, the fair market value of an ADS at vest of the awards was US$60.58, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Aradhana Sarin
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4i	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	AstraZeneca PLC American Depositary Shares CUSIP: 046353108
b)	Nature of the transaction	Acquisition of AstraZeneca PLC American Depository Shares pursuant to a vesting under the Global Restricted Stock Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) 0 67,677
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	28 February 2022
f)	Place of the transaction	Outside a trading venue

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

END

 

 

DSHUAUSRUOUORAR